Clinical Trial Update: Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial updates a neoadjuvant combination of iparomlimab, tuvonralimab, and lenvatinib for resectable hepatocellular carcinoma, and is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Hepatocellular Carcinoma Resectable | Phase 2 | Status: NOT_YET_RECRUITING